Compounds > deoxycytidine

deoxycytidine and Dihydropyrimidine Dehydrogenase Deficiency

deoxycytidine has been researched along with Dihydropyrimidine Dehydrogenase Deficiency in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (35.00)29.6817
2010's12 (60.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Black, PC; Contreras-Sanz, A; Eto, M; Hayashi, T; Inokuchi, J; Kang, D; Kiyokoba, R; Kohashi, K; Matsumoto, S; Matsumoto, T; Nagakawa, S; Noda, N; Oda, Y; Setoyama, D; Shiota, M; Takamatsu, D; Tsukahara, S; Uchiumi, T; Yagi, M1
Dołegowska, B; Ostapowicz, A1
Albini, A; Banzi, M; Boni, C; Casali, B; Farnetti, E; Focaccetti, C; Magnani, E; Nicoli, D; Savoldi, L1
Caudle, KE; Diasio, RB; Klein, TE; McLeod, HL; Schwab, M; Swen, JJ; Thorn, CF1
Ikeda, H; Kato, H; Kodera, M; Mizuno, K; Oishi, M; Seshimo, K; Toshima, T; Yamamura, M; Yamashita, Y1
Bank, PC; Guchelaar, HJ; Swen, JJ1
Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M1
Nagai, K; Ohara, Y; Okuda, Y; Yamamoto, M1
Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC1
Moore, S1
Bontemps, H; Coursier, S; Emptoz, J; Guillermet, A; Martelet, S; Villier, C1
Abali, H; Disel, U; Gürkut, O; Kaleağasi, H; Mertsoylu, H; Ozyilkan, O; Saif, MW1
Boot, H; Cats, A; Deenen, MJ; Schellens, JH; Terpstra, WE1
Beijnen, JH; Cats, A; Deenen, MJ; Mandigers, CM; Schellens, JH; Soesan, M; Terpstra, WE1
Haanen, JB; Hooiveld, EA; van Kuilenburg, AB; Westermann, AM1
Boyer, JC; Ciccolini, J; Dahan, L; Dales, JP; Durand, A; Evrard, A; Lacarelle, B; Mercier, C; Milano, G; Richard, K; Seitz, JF1
Diasio, R; Saif, MW1
Diasio, R; Elfiky, A; Saif, MW1
Ciccolini, J; Mercier, C1
Autret-Leca, E; Blasco, H; Boisdron-Celle, M; Bougnoux, P; Calais, G; Ciccolini, J; Le Guellec, C; Tournamille, JF1

Reviews

5 review(s) available for deoxycytidine and Dihydropyrimidine Dehydrogenase Deficiency

ArticleYear
[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Przeglad lekarski, 2012, Volume: 69, Issue:9

    Topics: Antineoplastic Agents; Biomarkers; Breath Tests; Capecitabine; Comorbidity; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Mutation; Neoplasms; Polymorphism, Single Nucleotide; RNA, Messenger; Uracil

2012
[A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:11

    Topics: Aged; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Fluorouracil; Humans; Male; Neutropenia; Thrombocytopenia

2013
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
    BMJ case reports, 2014, Apr-19, Volume: 2014

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Colitis; Contraindications; Deoxycytidine; Diagnosis, Differential; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Ileitis; Mutation; Neoplasm Metastasis; Triple Negative Breast Neoplasms

2014
Unanticipated toxicity to capecitabine.
    Oncology nursing forum, 2009, Volume: 36, Issue:2

    Topics: Antimetabolites, Antineoplastic; Black or African American; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Drug Monitoring; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Nursing Assessment; Oncology Nursing; Pharmacogenetics; Risk Factors; Safety; Vomiting

2009
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms; Polymorphism, Genetic

2006

Other Studies

15 other study(ies) available for deoxycytidine and Dihydropyrimidine Dehydrogenase Deficiency

ArticleYear
Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine.
    Scientific reports, 2022, 05-20, Volume: 12, Issue:1

    Topics: Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Gemcitabine; Genomics; Humans; Urinary Bladder Neoplasms

2022
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
    Internal and emergency medicine, 2013, Volume: 8, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Fluorouracil; Head and Neck Neoplasms; Heterozygote; Humans; Male; Mutation; Patient Selection; Polymerase Chain Reaction

2013
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
    Clinical pharmacology and therapeutics, 2013, Volume: 94, Issue:6

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genotype; Humans; Incidental Findings; Male; Risk Assessment; Sex Factors; Tegafur

2013
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.
    Internal and emergency medicine, 2014, Volume: 9, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Head and Neck Neoplasms; Humans; Male

2014
[Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; Male; Sigmoid Neoplasms

2015
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Uracil

2015
[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Gastroenterologie clinique et biologique, 2010, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Fluorouracil; Humans; Intensive Care Units; Male

2010
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
    Cutaneous and ocular toxicology, 2010, Volume: 29, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Atrophy; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Erythema; Fluorouracil; Foot; Functional Laterality; Hand; Humans; Male; Stomach Neoplasms

2010
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
    Annals of internal medicine, 2010, Dec-07, Volume: 153, Issue:11

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Prodrugs; Rectal Neoplasms; Tegafur

2010
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
    Nederlands tijdschrift voor geneeskunde, 2012, Volume: 156, Issue:48

    Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Female; Fluorouracil; Genetic Testing; Genotype; Humans; Male; Middle Aged; Neoplasms; Risk Assessment; Tegafur

2012
[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Nederlands tijdschrift voor geneeskunde, 2004, Mar-27, Volume: 148, Issue:13

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Humans; Leukocytes, Mononuclear; Middle Aged; Mutation; Neoplasm Recurrence, Local

2004
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); DNA Primers; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Tomography, X-Ray Computed

2006
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    Clinical colorectal cancer, 2006, Volume: 5, Issue:5

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms

2006
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Paresthesia; Prodrugs; Rectal Neoplasms; Syndrome

2006
A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
    British journal of clinical pharmacology, 2008, Volume: 65, Issue:6

    Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Drug Monitoring; Female; Fluorouracil; Humans; Polymorphism, Genetic

2008